---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-210298"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:00:08.307533+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa Q1 net loss $44.5M; cash $671M; multiple pipeline advances

## Summary
- Net loss of $44.5M vs net income of $46.9M in Q1 2025; collaboration revenue fell to $4.2M from $84.9M.
- Cash, equivalents, and securities total $671.2M as of March 31, 2026, sufficient into 2029; $345M public offering closed in Jan.
- MRT-8102 (NEK7 MGD) showed 85% CRP reduction in elevated CVD risk; Phase 2 studies in ASCVD, gout, and hidradenitis suppurativa planned H2 2026–H1 2027.
- MRT-2359 (GSPT1 MGD): Phase 2 in mCRPC with AR mutations anticipated Q3 2026 after positive interim data; supply deal with Johnson & Johnson.
- Novartis to initiate multiple Phase 2 studies of MRT-6160 (VAV1 MGD) in immune-mediated diseases in 2026; Monte Rosa eligible for up to $2.1B milestones.

## SEC filing metadata
- accession: 0001193125-26-210298
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000119312526210298/0001193125-26-210298-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000119312526210298/glue-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-210298
- JSON: https://secwatch.observer/filing/0001193125-26-210298.json
- Plain text: https://secwatch.observer/filing/0001193125-26-210298.txt

## Source-grounded claims
- claim_id: 82d0a8aed930c089a6c82db5ec6df3dd2f4f2652
  claim: Monte Rosa Therapeutics, Inc. reported financial results for the quarter ended March 31, 2026.
  evidence_excerpt: On May 7, 2026, Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826457/000119312526210298/0001193125-26-210298-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.